These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24993135)

  • 1. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1835-46. PubMed ID: 24993135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1857-65. PubMed ID: 24993136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
    Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
    [No Abstract]   [Full Text] [Related]  

  • 9. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multiple sclerosis: current therapies and future perspectives].
    Matsushita T
    Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis research: diagnostics, disease-modifying treatments, and emerging therapies.
    Costello K
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S14-23. PubMed ID: 24217187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
    Fox EJ; Rhoades RW
    Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.
    Berger JR
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A changing treatment landscape for multiple sclerosis: challenges and opportunities.
    Piehl F
    J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.